NexImmune EBITDA 2020-2024 | NEXI

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

NexImmune ebitda from 2020 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

NexImmune ebitda from 2020 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$145.5B
Vertex Pharmaceuticals (VRTX)	$119.4B
Gilead Sciences (GILD)	$114.5B
Bristol Myers Squibb (BMY)	$113.1B
CSL (CSLLY)	$84.9B
Regeneron Pharmaceuticals (REGN)	$80.4B
GSK (GSK)	$70.4B
Argenex SE (ARGX)	$36.7B
Alnylam Pharmaceuticals (ALNY)	$31.7B
BioNTech SE (BNTX)	$28.6B
Illumina (ILMN)	$22.8B
Biogen (BIIB)	$21.9B
BeiGene (BGNE)	$17.5B
Moderna (MRNA)	$16.1B
Genmab (GMAB)	$13.3B
Incyte (INCY)	$13.2B
Insmed (INSM)	$12.8B
BioMarin Pharmaceutical (BMRN)	$12.6B
Bio-Techne Corp (TECH)	$12B
Sarepta Therapeutics (SRPT)	$11.8B
Exact Sciences (EXAS)	$11.3B
Vaxcyte (PCVX)	$10.9B
QIAGEN (QGEN)	$10.4B
Exelixis (EXEL)	$10B
Bio-Rad Laboratories (BIO.B)	$9.4B
Intra-Cellular Therapies (ITCI)	$8.8B
Repligen (RGEN)	$8.8B
Roivant Sciences (ROIV)	$8.6B
Ascendis Pharma (ASND)	$7.9B
Revolution Medicines (RVMD)	$7.6B